Drugs firm set to be probed by fraud unit
Drugs giant GlaxoSmithKline's commercial practices are under criminal investigation by the UK's major fraud unit, the company has revealed.
The London-based multinational said in a statement that the Serious Fraud Office (SFO) has opened a "formal criminal investigation".
A spokesman said: "GSK is committed to operating its business to the highest ethical standards and will continue to co-operate fully with the SFO."
GSK has been at the centre of a slew of allegations in recent months from investigators in China, Iraq and Poland, after company reps were alleged to have paid doctors and hospital officials to prescribe its products ahead of others.
Earlier this month, Chinese police accused Mark Reilly, a senior executive, of pressing his sales team to bribe doctors, hospital officials and health institutions, allegedly resulting in "illegal revenue" of billions of yuan.
Reilly and two Chinese executives were also accused of bribing government officials in Beijing and Shanghai.